Maribel Chahine, MS

Although evidence supports safety of apixaban and rivaroxaban relative to warfarin, researchers had not directly compared their bleeding risk until last year.

Inflammation fuels residual ASCVD risk; survey reveals hs-CRP testing gaps, persistent angina, and new therapies for cardiovascular health.